Department of Cardiovascular Surgery, Hôpital Georges Pompidou, Paris, France.
Eur J Cardiothorac Surg. 2012 Jan;41(1):87-92. doi: 10.1016/j.ejcts.2011.05.027.
This study aimed at evaluating the clinical and angiographic results of the radial artery (RA) used as a coronary bypass graft over 20 years.
Clinical follow-up was obtained in 563 patients at 9.2 years. Angiographic follow-up was obtained in 351 patients with opacification of 1427 conduits, including 629 RA at 7.0 years.
At 9.2 years, freedom from overall and cardiovascular death was 80.3% and 92.7%, respectively. Symptoms were: acute myocardial infarction: 2.1% (n=12); angina: 17.4% (n=98), and congestive heart failure 10.6% (n=60). Percutaneous revascularization was required in 13.5% (n=76) of cases on: native coronary (n=77), RA conduit (n=21), and other graft (n=7). Reoperation was needed in 2.3% (n=13) of cases for valve replacement (n=10) and redo coronary artery bypass grafting (CABG) (n=3). At 7.0 years, RA patency was 82.8% (521/629) and was lower than that of left internal mammary artery (IMA), 95.5% (491/514) (p<0.001); similar to right IMA, 87.9% (51/58, p=0.32); free IMA, 80.0% (44/55, p=0.60); and vein, 81.9% (140/171, p=0.77). RA patency was lower in the case of myocardial ischemia: 74.0% (174/235) versus 88.1% (347/394) in asymptomatics (p<0.001). RA patency was higher for diagonal (93.1% (95/102)) compared to circumflex (82.5% (274/332, p<0.01)) and right coronary (77.6% (146/188, p<0.001)). Calcium channel blockers had no impact on RA patency. Separating four groups at successive follow-up intervals, RA patency was: 86.2%, 81.9%, 81.4%, and 81.6% at 1.0, 5.4, 8.3, and 13.1 years, respectively.
CABG with the RA offered long-lasting clinical benefit. Beyond the first postoperative year during which some attrition was observed, RA patency was remarkably stable for up to 20 years.
本研究旨在评估桡动脉(RA)作为冠状动脉旁路移植术 20 多年来的临床和血管造影结果。
563 例患者在 9.2 年时获得临床随访。351 例患者行血管造影随访,1427 条导管显影,其中 629 条 RA 在 7.0 年时显影。
9.2 年时,总体和心血管死亡率分别为 80.3%和 92.7%。症状为:急性心肌梗死:2.1%(n=12);心绞痛:17.4%(n=98),充血性心力衰竭 10.6%(n=60)。13.5%(n=76)的病例需要经皮血运重建:原生冠状动脉(n=77)、RA 导管(n=21)和其他移植物(n=7)。2.3%(n=13)的病例需要再次手术,用于瓣膜置换术(n=10)和再次冠状动脉旁路移植术(CABG)(n=3)。7.0 年时,RA 通畅率为 82.8%(521/629),低于左内乳动脉(IMA)的 95.5%(491/514)(p<0.001);与右 IMA 相似,87.9%(51/58,p=0.32);游离 IMA,80.0%(44/55,p=0.60);静脉,81.9%(140/171,p=0.77)。有心肌缺血的病例 RA 通畅率较低:74.0%(174/235)与无症状患者的 88.1%(347/394)相比(p<0.001)。RA 通畅率在对角支(93.1%(95/102))高于回旋支(82.5%(274/332,p<0.01))和右冠状动脉(77.6%(146/188,p<0.001))。钙通道阻滞剂对 RA 通畅率没有影响。将四个随访间隔分组后,RA 通畅率分别为:1.0 年时为 86.2%,5.4 年时为 81.9%,8.3 年时为 81.4%,13.1 年时为 81.6%。
RA 冠状动脉旁路移植术提供了持久的临床益处。在第一个术后年出现一些损失后,RA 通畅率在长达 20 年的时间内保持显著稳定。